Related Experiment Video
Updated: Jun 20, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Accelerated cellular senescence in myelodysplastic syndrome
Yuan-Yuan Wang1, Jian-Nong Cen, Jun He
1The First Affiliated Hospital, Suzhou University, Jiangsu Institute of Hematology, Leukemia Research Division, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Suzhou 215006, China.
Cellular senescence, a marker of aging cells, is accelerated in myelodysplastic syndromes (MDS). This senescence may play a role in MDS progression and patient outcomes.
Area of Science:
- Hematology
- Cell Biology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Cellular senescence is implicated in aging and various diseases.
Purpose of the Study:
- To investigate the role of cellular senescence in the progression and prognosis of MDS.
Main Methods:
- Analyzed p16INK4a expression in bone marrow cells from MDS, acute myeloid leukemia (AML), and healthy controls.
- Assessed senescence-associated beta-galactosidase (SA-beta-gal) activity in patient cells and cell lines.
Main Results:
- Upregulated p16INK4a expression and increased SA-beta-gal activity were observed in MDS patients compared to controls.
- p16INK4a expression negatively correlated with International Prognostic Scoring System scores.
- Senescence markers were higher in dysplastic cells within MDS samples.
Conclusions:
- Accelerated cellular senescence occurs in MDS.
- Cellular senescence may contribute to MDS progression and influence patient prognosis.
Related Concept Videos
Replicative Cell Senescence
Replicative Cell Senescence
Abnormal Proliferation
Differentiation of Common Myeloid Progenitor Cells
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle

